Citations 1
Comparison of Patient-Reported Peripheral Neuropathy Among Patients Treated With Elranatamab Versus Real-World Clinical Practice in Triple-Class Refractory Multiple Myeloma
Charalampous, Charalampos , Parrondo, Ricardo , Nagaraj, Madhu , Rodríguez‐Otero, Paula , Iida, Shinsuke , Raab, Marc S. , Mateos, María‐Victoria , Duh, Mei Sheng , Bobbili, Priyanka , Chen, Jingyi , Chaudhary, Mohammad A. , Hlavacek, Patrick , Nador, Guido, DiBonaventura, Marco , Goldman, Erinn Hoag, Hughes, David , Kumar, Shaji , Raab, Marc S , Parrondo, Ricardo D , Rodriguez-Otero, Paula , Chhabra, Saurabh , Nagaraj, Madhu , Wang, Aolin , Mohty, Mohamad
JCO Oncology Advances | October 7, 2025 | Volume: No volume available | Issue: 2 | Pages: No page available
PURPOSE This analysis aimed to contextualize the symptoms of peripheral neuropathy (PN) experienced by patients with triple-class refractory (TCR) multiple myeloma (MM) treated with elranatamab in the MagnetisMM-3 clinical trial with those experienced by patients with TCR MM receiving a new line of physician's choice of therapy in the real-world MagnetisMM-14 study. METHODS MagnetisMM-3 included 123 patients and MagnetisMM-14 included 35 who had TCR MM and were enrolled under the same eligibility criteria. Patient-reported symptoms of PN were collected monthly using the Chemotherapy-Induced Peripheral Neuropathy-20 item (CIPN20) questionnaire and compared for clinically meaningful differences across sensory, motor, and autonomic domains. Higher scores indicated worse patient-reported PN symptoms. RESULTS Baseline demographics and clinical characteristics for patients in MagnetisMM-3 and MagnetisMM-14 were generally similar. Patients in MagnetisMM-3 had a median of five ( v four in MagnetisMM-14) prior lines of therapy. In MagnetisMM-14, common index therapies included elotuzumab + pomalidomide (23%), carfilzomib + pomalidomide (19%), or carfilzomib + cyclophosphamide (19%), all with corticosteroids. Mean scores for sensory (15.8 v 14.8) and motor (14.4 v 12.2) domains of the CIPN20 were similar between MagnetisMM-3 and MagnetisMM-14 at baseline. Mean scores for the autonomic domain were 14.0 versus 21.3 at baseline, respectively. No clinically meaningful differences for any domain were found between month 6 scores or changes in scores from baseline to month 6 between MagnetisMM-3 and MagnetisMM-14 populations. CONCLUSION These findings suggest that elranatamab treatment was not associated with a worsening of patient-reported PN symptoms across the sensory, motor, and autonomic domains of the CIPN20. Moreover, PN symptoms reported with elranatamab treatment were similar to those reported with other common therapies used in real-world clinical practice for the management of MM. MagnetisMM-3 ClinicalTrials.gov identifier: NCT04649359 .